,answer,docs,question,faithfulness,answer_relevance,context_precision,sum,target_article
0,"The provided documents do not contain sufficient information about the effect of TR-ZRA nanoparticles on CD22 expression specifically in BV2 cells after exposure to Aβ1-42. However, the documents state that in mice, CD22 expression was significantly lower in the AD-TR-ZRA group compared to the AD group, indicating that CD22shRNA loaded with ZC effectively inhibited gene expression (Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease, https://doi.org/10.1002/advs.202301361). 

The Western blotting (WB) results indicate that the expression of CD22 in the AD-TR-ZRA group was significantly lower than that in the AD group (Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease, https://doi.org/10.1002/advs.202301361). This suggests the delivered CD22shRNA effectively inhibited gene expression.","[Document(id='f68f4706-c778-4647-934f-672cac74416b', metadata={'year': 2023, 'title': ""Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease"", 'id': 50, 'type': 'result', 'file': '17.pdf', 'link': 'https://doi.org/10.1002/advs.202301361'}, page_content='Figure 9c and Figure S17, Supporting Information, there were a number of dead cells after incubation with Aβ1-42 alone for 24 h. In addition, free ZC or CD22shRNA had little effect due to their poor cellular uptake and Aβ clearance. Nevertheless, the number of dead cells decreased significantly after treatment with TR-ZRA medium, which means that the cells’ functions had been improved. This indicated that the TR-ZRA nanoparticles could reduce'), Document(id='8f13017c-efc9-4731-8f66-7d6f59a222fd', metadata={'year': 2023, 'title': ""Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease"", 'id': 50, 'file': '17.pdf', 'type': 'result', 'link': 'https://doi.org/10.1002/advs.202301361'}, page_content='mice was employed for WB and immunofluorescence assays. The WB results showed that the expression of CD22 in the AD-TR-ZRA group was significantly lower than that in the AD group, indicating that CD22shRNA loaded with ZC effectively inhibited gene expression (Figure 7e,f). In addition, as observed in the immunofluorescence assay, CD22 expression (green) was significantly downregulated in IBA1-labeled microglia (red) after TR-ZRA treatment'), Document(id='864f03d9-a54f-4bcb-be4e-9cede0dcb216', metadata={'file': '17.pdf', 'type': 'result', 'year': 2023, 'id': 50, 'title': ""Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease"", 'link': 'https://doi.org/10.1002/advs.202301361'}, page_content='In addition, a gel electrophoresis assay was adopted to evaluate the complexation ability of CD22shRNA and Aβ aptamer. As shown in Figure 2e, ZC-AAP formation was limited to the initial gum hole when each micromole of AAP could combine with 0.27 μg or more ZC (the ratio was ≈4:15). In the same way, there was no free AAP or CD22shRNA at the bottom of the gel when 1 μg CD22shRNA was carried by 8 μg ZC-AAP (with a surface-mass ratio of 8:1) (Figure'), Document(id='91fa58b7-df65-4db2-bf35-9f432395fe9a', metadata={'type': 'result', 'file': '6.pdf', 'link': 'https://doi.org/10.1016/j.apsb.2022.02.001', 'title': ""Intelligent lesion blood–brain barrier targeting nano-missiles for Alzheimer's disease treatment by anti-neuroinflammation and neuroprotection"", 'year': 2022, 'id': 20}, page_content='the A b plaques burden was significantly reduced by 1.64 times after the treatment of Ibu&FK@RNPs and there was no statistic difference in combination drug treatment ( Fig. 5 F). This result indicates the combination medication could specifically inhibit the production of toxic isoform A b plaques. However, the modification of nanocarriers had few efficacies in reducing A b plaques. In AD, A b plaques and tau tangles work together to increase'), Document(id='32825a29-c3a7-46fc-a542-348fa2e7b62d', metadata={'type': 'result', 'link': 'https://doi.org/10.1002/advs.202301361', 'id': 50, 'year': 2023, 'title': ""Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease"", 'file': '17.pdf'}, page_content='IL-1β, TNF-α, and IL-6 were obviously increased when BV2 cells were cocultured with Aβ1-42 or the commercial transfection reagent Lipo, which might be associated with the toxicity caused by Aβ1-42 or Lipo. The levels of these proinflammatory cytokines remained relatively high after ZC treatment alone, which might be due to the correlation between cellular uptake of the drug and the level of intracellular gene expression in aging BV2 cells.')]","What effect do TR-ZRA nanoparticles have on CD22 expression in BV2 cells after exposure to Aβ1-42, and what does the Western blotting result indicate about the delivered CD22shRNA?",2,2,2,6,1
1,"The VTA volume is strongly associated with the size of the hippocampal formation in Alzheimer's disease patients (and healthy controls) – a smaller VTA size or shrinkage of the nucleus might correspond to a smaller hippocampal formation ([“The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease”, https://doi.org/10.3389/fpsyt.2022.1039725])","[Document(id='53dd2f82-2471-4ffe-8845-e17e3ac2fb83', metadata={'id': 29, 'link': 'https://doi.org/10.3389/fpsyt.2022.1039725', 'title': ""The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease"", 'file': '9.pdf', 'year': 2022, 'type': 'result'}, page_content='structural MRI to link the volume of the VTA with typical AD clinical markers, in particular hippocampal size and memory index (133, 134). The main finding of the study was that the VTA volume is strongly associated with the size of the hippocampal formation and memory abilities of both AD patients and healthy controls, thus indicating that a smaller VTA size or shrinkage of the nucleus might correspond to a worse memory performance and smaller'), Document(id='de6c5895-3eba-4ef0-af8b-13ac5e6572c7', metadata={'link': 'https://doi.org/10.26508/lsa.202402650', 'type': 'introduction', 'title': 'Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab', 'year': 2024, 'id': 67, 'file': '23.pdf'}, page_content='different reports regarding the quantity of Aβ variants, which vary depending on the methods employed. For instance, the group led by Michel Goedert, who used MALDI-TOF mass spectrometry and LC-MS/MS to resolve the cryo-EM structure of Aβ42 filaments from human brains, recently indicated that Aβ3pE-42 was a minor variant in the brains of AD patients and App knock-in (KI) mice (Yang , 2022). This inconsistency can be accounted for by the unique'), Document(id='71e9781f-22e8-4bd1-bc65-2dc4ab6e52dd', metadata={'link': 'https://doi.org/10.3389/fnagi.2021.809433', 'year': 2022, 'type': 'result', 'id': 2, 'title': ""Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis"", 'file': '0.pdf'}, page_content='compared with the regular group. Increased yellowish-brown A β plaque deposition and brown P-Tau deposits in the model group. Conversely, treatment with Sal or DNP marked reduced the positive area of A β and P-Tau in the hippocampal region, the yellowish-brown A β plaque deposition and brown P-Tau deposits are both decreased, with a signiﬁcant diﬀerence compared with the A β 1-42 group (Figures 5A,B). In short, the above results demonstrated'), Document(id='a50adc17-751a-471b-a9fb-aa213cfa0185', metadata={'type': 'result', 'link': 'https://doi.org/10.1016/j.nbd.2024.106505', 'file': '4.pdf', 'title': ""Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects"", 'year': 2024, 'id': 14}, page_content='and more severe PD symptoms. Meanwhile, elevated dihydrosphingomyelin (dhSM) and plasmenylethanolamine (PEp) are associated with lower UPDRS scoring and comparatively milder presentations of the disease (Avisar ., 2021). From the standpoint of brain structure and function, brain imaging methods include diffusion tensor imaging (DTI), positron emission tomography (PET), structural magnetic resonance imaging (sMRI), and functional magnetic'), Document(id='ad28955a-fbcd-44e1-8575-f19d8b629bd1', metadata={'type': 'result', 'year': 2021, 'title': ""A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease"", 'id': 53, 'link': 'https://doi.org/10.1016/j.xinn.2021.100160', 'file': '18.pdf'}, page_content='wild-type (WT) mice showed a preference for the target quadrant, while untreated APP/PS1 mice rarely swam across it (Figures 3D and 3H). Similarly, PTCN treatment signiﬁcantly increased the number of crossings of APP/PS1 mice over the platform in both the preventive and therapeutic trials (Figures 3E and 3I). Then, we evaluated hippocampal volume changes by magnetic resonance imaging (MRI) since hippocampal atrophy is a recognized biolog-ical')]","According to structural MRI studies, what is the relationship between the volume of the Ventral Tegmental Area (VTA) and the hippocampal formation in Alzheimer's disease patients?",3,3,2,8,1
2,"According to the provided documents, protein contents were in the order of APN > APA > DPP4, but DPP4 had the highest specific activity (https://doi.org/10.26508/lsa.202402650).","[Document(id='6a5b1a60-98ba-461b-adb9-594c6e8362ad', metadata={'type': 'result', 'year': 2024, 'link': 'https://doi.org/10.26508/lsa.202402650', 'id': 68, 'title': 'Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab', 'file': '23.pdf'}, page_content='and dipeptidyl peptidase 4 (DPP4), which were immunopurified from the membrane fraction of mouse brains, displayed Aβ-degrading activity (Fig 7A). Among them, DPP4 exhibited the highest activity. Protein contents were in the order of APN > APA > DPP4, but DPP4 had the highest specific activity (Fig 7C), suggesting that it plays a significant role in truncating amino-terminal amino acids (DA). Our results showed that the expression levels of APN,'), Document(id='72d93a76-972a-4bbd-9618-d34c59d1190d', metadata={'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'id': 44, 'year': 2024, 'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease"", 'type': 'result', 'file': '15.pdf'}, page_content='that the minor allele of rs4878104 is associated with increased total CSF Aβ level [96]. However, by comparing brain samples from AD patients and healthy controls, Hainsworth . revealed that the expression of DAPK1 in the frontal cortex is not significantly different between AD and control cases. Moreover, the abundance of DAPK1 in the brain is also not correlated with Aβ level [97]. Thus far, there is still a lack of consistent molecular'), Document(id='2fd4ab83-c092-48f9-9bca-9868d7f0aec7', metadata={'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'year': 2024, 'file': '15.pdf', 'id': 44, 'type': 'result', 'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease""}, page_content='caspase-3-dependent neuronal cell death [156]. We recently demonstrated that both low- and high-molecular-weight Aβ species upregulate DAPK1 protein levels in neurons and cause extensive neuronal apoptosis [135]. Additionally, the upregulation of DAPK1 by Aβ oligomers leads to Ca2+ overload and excitotoxicity in the SH-SY5Y cell line via phosphorylation of the Ser1303 residue of the NMDAR GluN2B subunit, resembling the effect observed in an'), Document(id='5dd717ed-3f84-449c-a38c-d33d9b6c5ad5', metadata={'id': 68, 'type': 'result', 'link': 'https://doi.org/10.26508/lsa.202402650', 'year': 2024, 'title': 'Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab', 'file': '23.pdf'}, page_content='Furthermore, we found that Aβ3pE-40/42, but not Aβ1-40/42, colocalized well with apolipoprotein E (ApoE), which is known to be involved in Aβ aggregation (Nilsson , 2004), in the cores of amyloid plaques (Fig S7A). Intensities of ApoE-positive signals in the amyloid plaques and levels of ApoE and α1-antichymotrypsin in the soluble fraction were significantly elevated by the Mme deficiency in the 24-mo-old APP-Tg mice (Fig S7B and C). These'), Document(id='528b7806-ada8-49fe-9d26-f5723af06830', metadata={'title': ""Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease"", 'id': 50, 'file': '17.pdf', 'type': 'result', 'link': 'https://doi.org/10.1002/advs.202301361', 'year': 2023}, page_content='showed that the fluorescence signal of AAP increased gradually with increasing Aβ1-42 concentration, which indicated that AAP can indicate the Aβ1-42 concentration in vitro under certain conditions (Figure S10a, Supporting Information). In addition, the same concentrations of Aβ1-42 and BSA were incubated with different concentrations of AAP (0–160 μg mL−1) for 2 h at 37 °C to explore the reactivity of AAP (Figure 6c). Meanwhile, as shown in the')]","Compare the Aβ-degrading enzymes APN, APA, and DPP4: which one has the highest protein content, and which one exhibits the highest specific activity?",3,3,3,9,1
3,"**The established role of Transthyretin (TTR) in Alzheimer's Disease (AD) is neuroprotection** (""Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease"", https://doi.org/10.1016/j.ejmech.2021.113847). **Small-molecule compounds are being developed as chaperones to enhance TTR/Amyloid-beta peptide (Aβ) interactions** (""Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease"", https://doi.org/10.1016/j.ejmech.2021.113847)","[Document(id='a9429100-52b6-42b3-8ea9-bab4f783e097', metadata={'id': 33, 'title': ""Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease"", 'year': 2021, 'file': '12.pdf', 'type': 'abstract', 'link': 'https://doi.org/10.1016/j.ejmech.2021.113847'}, page_content=""Transthyretin (TTR) has a well-established role in neuroprotection in Alzheimer's Disease (AD). We have setup a drug discovery program of small-molecule compounds that act as chaperones enhancing TTR/Amyloid-beta peptide (Aβ) interactions. A combination of computational drug repurposing approaches and in vitro biological assays have resulted in a set of molecules which were then screened with our in-house validated high-throughput screening""), Document(id='3b66dd66-31b6-4970-a6ca-ac4b50095143', metadata={'year': 2023, 'id': 17, 'title': ""Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy"", 'file': '5.pdf', 'link': 'https://doi.org/10.4103/1673-5374.385847', 'type': 'result'}, page_content='the seeding and spreading of Aβ-related tau (Jain ., 2023), several earlier studies have presented the beneficial effects of TREM2 agonist antibodies in private amyloid pathology (Wang ., 2020b; Zhao ., 2022). A possible explanation may be that the activation of TREM2 downstream signaling, such as nuclear factor κB signaling, could exacerbate tau spread and toxicity in an Aβ-independent manner (Wang ., 2022). Other AD risk factors are enriched'), Document(id='baa06d1e-53ef-49ac-ba81-1026aa903d71', metadata={'id': 44, 'year': 2024, 'type': 'result', 'file': '15.pdf', 'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease""}, page_content='of proteins [133]. With accumulation of intracellular Aβ species, molecular chaperones such as HSP90 may function to antagonize the cellular stress caused by the excessive misfolded proteins [134]. We recently observed that the primary neurons incubated with Aβ aggregates have a higher DAPK1 protein level than those without Aβ treatment [135]. However, the DAPK1 mRNA level is not altered by Aβ, which is in line with our previous findings in'), Document(id='d6fb3df5-4642-462c-8261-024acd5519e1', metadata={'link': 'https://doi.org/10.1016/j.nbd.2024.106505', 'file': '4.pdf', 'title': ""Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects"", 'type': 'result', 'id': 14, 'year': 2024}, page_content='(Mett, 2021; Wang ., 2021). Furthermore, cholesterol impacts the polymerization of APP and γ-secretase’s processing of APP, leading to the generation of Aβ with diverse levels of toxicity and aggravation of Alzheimer’s Disease (Wu ., 2022). High cholesterol levels in neurons encourage Aβ-induced oxidative stress in mitochondria and impede the fusion of the dysfunctional mitochondria with lysosomes (de Dios ., 2023; Howe ., 2022), which increases'), Document(id='20d2cfc0-0a36-4e2f-8267-04db148f28f8', metadata={'id': 34, 'file': '12.pdf', 'type': 'introduction', 'title': ""Targeting transthyretin in Alzheimer's disease: Drug discovery of small-molecule chaperones as disease-modifying drug candidates for Alzheimer's disease"", 'year': 2021, 'link': 'https://doi.org/10.1016/j.ejmech.2021.113847'}, page_content='that also occurs in the AD brain [33]. TTR tetrameric stability appears as a key factor in its interaction with Ab peptide. Interestingly, TTR stability is also a key factor in Familial Amyloid Polyneuropathy (FAP) [ 34,35] a systemic amyloidosis with a special involvement of the peripheral nerve system, which results from the aggregation, deposition and toxicity of mutated TTR. Since it is believed that tetramer dissociation into monomers is')]","What is the established role of Transthyretin (TTR) in Alzheimer's disease, and how are small-molecule chaperones expected to affect the interaction between TTR and Aβ peptide?",3,3,2,8,1
4,"Compounds targeting p38 MAPK, ERK1/2, JNK3 or several tyrosine kinases have been evaluated in AD mouse models [https://doi.org/10.1186/s40035-023-00395-5].","[Document(id='e3f39247-df6f-49e4-a545-9c1dab5e4059', metadata={'year': 2024, 'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'id': 44, 'type': 'result', 'file': '15.pdf', 'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease""}, page_content='to overcome these drawbacks [223]. Protein kinases are valuable therapeutic targets for the intervention of AD, not only due to the direct participation of dysregulated kinases in various AD pathologies, but also because of the vast number of chemicals and strategies available for drug development [227]. Compounds targeting GSK-3β, CDK5, p38 MAPK, ERK1/2, JNK3 or several tyrosine kinases have been evaluated in AD mouse models, and some of them'), Document(id='c326fa8a-c0d6-4e71-b091-b5ad38b947db', metadata={'year': 2024, 'title': ""GSK3: A potential target and pending issues for treatment of Alzheimer's disease"", 'id': 11, 'link': 'https://doi.org/10.1111/cns.14818', 'file': '3.pdf', 'type': 'result'}, page_content='(Figure 4). The association between GSK3 activation and A β pathology has been observed in numerous cellular or animal models. CDK5 knockdown in 3×Tg- AD mice executed at the age of 15 months, showed significant reduction in amyloid plaques. The activation of GSK3 β and PP2A was declared to be the primary reason. 203 The author of this report primarily focuses on the association between CDK5 and GSK3β. Unfortunately, the direct cause of GSK3 β'), Document(id='50d9089f-3e6e-4c62-98f4-70205af240f3', metadata={'type': 'result', 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'id': 74, 'file': '26.pdf', 'year': 2022, 'link': 'https://doi.org/10.1016/j.patter.2021.100433'}, page_content='proteins that were found to be associated with AD (Figure 4B; Data S3). It was not surprising that quercetin and GW441756X would have additional targets of interest, as these compounds were found to interact with the greatest number of molecules from those in our list (80 and 62, respectively). Interestingly, of the eight overlapping hits from the AD association analysis, three were found to be targeted by multiple drugs in our list. CDK1 and'), Document(id='1435f3c3-443d-4b30-b0c4-9c662e88bc2f', metadata={'type': 'result', 'id': 11, 'link': 'https://doi.org/10.1111/cns.14818', 'title': ""GSK3: A potential target and pending issues for treatment of Alzheimer's disease"", 'year': 2024, 'file': '3.pdf'}, page_content='to inhibit GSK3 and p- tau but have no effect on CDK5.332'), Document(id='f18f6ab1-e82e-4f8f-9f71-0d6cd506d4b8', metadata={'year': 2023, 'file': '22.pdf', 'id': 65, 'title': 'Targeting the post-synaptic proteome has therapeutic potential for psychosis in Alzheimer Disease', 'type': 'result', 'link': 'https://doi.org/10.1038/s42003-023-04961-5'}, page_content='altered kinases and may provide another metric to assess the therapeutic potential of other drug candidates. We report theﬁrst study, to our knowledge, to directly inter-rogate the PSD in AD+ P. The abundance of numerous PSD proteins was reduced in AD + P relative to both AD-P and comparison subjects. Examination of the PSD proteome signature of AD+ P, relative to AD-P, revealed lower levels of an inter-acting set of protein kinases, regulators')]","List the kinases, other than GSK-3β and CDK5, whose inhibitors have been evaluated in AD mouse models according to the text.",3,3,2,8,1
5,"In Hsp27 transgenic mice, p-GSK3βTyr216 is upregulated and p-GSK3βSer9 is downregulated, indicating that GSK3β is the immediate cause of pathological tau phosphorylation (""GSK3: A potential target and pending issues for treatment of Alzheimer's disease"", https://doi.org/10.1111/cns.14818).","[Document(id='934a614d-2986-4365-99d2-dd951794ec25', metadata={'file': '3.pdf', 'link': 'https://doi.org/10.1111/cns.14818', 'year': 2024, 'title': ""GSK3: A potential target and pending issues for treatment of Alzheimer's disease"", 'type': 'result', 'id': 11}, page_content='Heat shock protein 27 (Hsp27) transgenic mice showed a striking pathological phosphorylation of tau, with upregulated p- GSK3βTyr216 and downregulated p- GSK3βSer9 indicating that GSK3 β was the immediate cause of p- tau.146 Increased expression of p44, a short isoform of p53, has been found to elevate the risk of tau pathology.147 Moreover, haploinsufficiency for p73, a member of the p53 family, has demonstrated a similar phenomenon. 148'), Document(id='2e2c8f04-4aca-44c5-8ffa-18aa03bddb0d', metadata={'title': ""GSK3: A potential target and pending issues for treatment of Alzheimer's disease"", 'type': 'result', 'link': 'https://doi.org/10.1111/cns.14818', 'year': 2024, 'file': '3.pdf', 'id': 11}, page_content='mice. 78 Specifically, GSK3 overexpression or excessive activation also damages substructures within neurons, such as synapses, dendrites, and axons. GSK3 β overexpression can inhibit synaptogenesis. 79 In rats with elevated GSK levels caused by exogenous or endogenous factors, the presynaptic active zone, postsynaptic density, and synaptic cleft are all negatively affected, accompanied by long- term potentiation (LTP) inhibition. 80 LTP'), Document(id='464f9958-46ef-4115-8bd9-d0b7adb0d30d', metadata={'id': 10, 'file': '3.pdf', 'type': 'introduction', 'year': 2024, 'link': 'https://doi.org/10.1111/cns.14818', 'title': ""GSK3: A potential target and pending issues for treatment of Alzheimer's disease""}, page_content='by research.5,6 These isoforms are derived from chromosome 19 and chromosome 3, respectively. 6,7 Both GSK3 α and GSK3 β have been detected in almost all species, with over 90% similarity across different species. 8 In Homo sapiens, the amino acid sequences of GSK3α and GSK3 β show 84%–85% similarity, while their kinase domains exhibit a high degree of homology, with 19 differential amino acids from the 285 amino acids that make up the kinase'), Document(id='fb9dafb7-96bb-4937-9845-7c9e8bfad6cf', metadata={'title': ""GSK3: A potential target and pending issues for treatment of Alzheimer's disease"", 'type': 'result', 'year': 2024, 'file': '3.pdf', 'link': 'https://doi.org/10.1111/cns.14818', 'id': 11}, page_content='125 The aforementioned proteins involve cellular signal transduction and intracellular and extracellular substance exchange. While a few studies have observed changes in their levels associated with alterations in the PI3K/AKT/GSK3β signaling pathway, this phenomenon is likely the result of multiple factors influencing it, such as insulin signaling, lipid transport, and metabolism. The underlying mechanisms by which these factors ultimately'), Document(id='e1345373-881b-4009-93fe-9c1e999f10fd', metadata={'id': 11, 'link': 'https://doi.org/10.1111/cns.14818', 'title': ""GSK3: A potential target and pending issues for treatment of Alzheimer's disease"", 'file': '3.pdf', 'type': 'result', 'year': 2024}, page_content='A β pathology, and several literature reports provide strong evidence supporting this inference. As a kinase of glycogen synthase, the over- activation of GSK3 is one of the causes of glucose metabolism disorder leading to diabetes. Advanced glycation end products (AGEs) are toxic substances generated in the body after long- term hyperglycemia. 7 Receptor for AGEs (RAGE) had been established to contribute to amyloid pathology. GSK3β and p38 were')]","In Hsp27 transgenic mice, how are p-GSK3βTyr216 and p-GSK3βSer9 levels altered, and what pathological consequence does this alteration cause?",3,3,3,9,1
6,"The provided documents do not contain sufficient information about the confidence score threshold set in the STRING database to construct the PPI network for quercetin's common targets in Type 2 Diabetes and Alzheimer's disease. The documents mention a PPI network was created (Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus, https://doi.org/10.1038/s41598-021-02248-5), and describe its characteristics (number of edges and nodes), but do not specify the confidence score used.","[Document(id='549d9f85-704e-4a81-a72d-f65ddc24c1c0', metadata={'file': '20.pdf', 'id': 57, 'link': 'https://doi.org/10.1038/s41598-021-02248-5', 'title': 'Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus', 'year': 2021, 'type': 'abstract'}, page_content='Quercetin has demonstrated antioxidant, anti-inflammatory, hypoglycemic, and hypolipidemic activities, suggesting therapeutic potential against type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD). In this study, potential molecular targets of quercetin were first identified using the Swiss Target Prediction platform and pathogenic targets of T2DM and AD were identified using online Mendelian inheritance in man (OMIM), DisGeNET, TTD,'), Document(id='47eb1832-4ad4-4205-8084-7be7838891c7', metadata={'file': '20.pdf', 'link': 'https://doi.org/10.1038/s41598-021-02248-5', 'title': 'Mechanism of quercetin therapeutic targets for Alzheimer disease and type 2 diabetes mellitus', 'id': 59, 'type': 'result', 'year': 2021}, page_content='top 25 targets (arranged in descending order of relevance as a concentric circle in Fig. 3A). The PPI network (Fig. 3B) includes 273 edges among the 95 nodes (circles), where edge thickness represents the interaction strength. To further refine the list of quercetin targets relevant to T2DM and AD treatment, we conduct cluster analysis on the PPI network based on shared mechanisms using MCODE. This analysis yielded a function module of five key'), Document(id='b13e7ddf-ac8c-4f39-b831-f75a484ede4a', metadata={'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'type': 'result', 'id': 74, 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'year': 2022, 'file': '26.pdf'}, page_content='and 5.98 for ‘‘glioblastoma’’ (GW441756X), whereas indirubin-3 0-monoxime appeared in an inflammatory context first (‘‘prostatitis’’ relevance score: 3.67), followed by ‘‘hemangiosarcoma’’ (relevance score: 3.65). For quercetin, a broad range of disease context information could be identified (Figures S4 and S5; Data S4). All four compounds were mentioned together with the MeSH terms ‘‘arthritis,’’ ‘‘asthma,’’ ‘‘colitis,’’ ‘‘fibrosis,’’'), Document(id='96ccb622-c5fe-410e-ac1a-0b0324acde6d', metadata={'link': 'https://doi.org/10.1016/j.nbd.2024.106505', 'file': '4.pdf', 'year': 2024, 'type': 'introduction', 'id': 13, 'title': ""Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects""}, page_content='the global prevalence of dementia is estimated to nearly double from current levels. However, if defined according to biological rather than solely clinical criteria for AD, the predicted rise in dementia cases may be even greater, potentially tripling in scale based on the available data (Nowell ., 2023; Scheltens ., 2021). Furthermore, PD has a significant influence on human health as the second most prevalent neurological illness after AD. In'), Document(id='d49f6849-e691-4096-92ce-5352b72a86ba', metadata={'file': '26.pdf', 'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'year': 2022, 'type': 'result', 'id': 74, 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism'}, page_content='targeted by multiple drugs in our list. CDK1 and CSNK2A1 are both targets of quercetin and GW441756X, while GSK3B was also found to be modulated by these compounds as well as indirubin-3 0-monoxime. Based on the information collected from the GWAS Catalog, we were able to calculate what percentage of each compound’s target list was associated with AD (Figure 4C). We found that indirubin-30-monoxime had the highest score, with 33.3% of its')]",What confidence score threshold was set in the STRING database to construct the PPI network for quercetin's common targets in Type 2 Diabetes and Alzheimer's disease?,3,2,2,7,1
7,"According to the provided documents, 23 molecules were found to be specific for the histone H3 substrate out of the 104 compounds that inhibited HDAC6 to at least 75% in the second screening. (A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism, https://doi.org/10.1016/j.patter.2021.100433)","[Document(id='71e4129b-b00a-4b07-86ec-e5111663405a', metadata={'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'file': '26.pdf', 'type': 'result', 'year': 2022, 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'id': 74}, page_content='confirmation rate is reasonable for this type of complex and coupled enzymatic assay. To validate the 183 confirmed active compounds, a second HDAC6 screening was conducted in addition to dose response studies (Figure 3D). This assay employing a shorter, less specific peptide derived from histone H3 resulted in 104 compounds inhibiting to at least 75%. From these, 23 molecules were found to be specific for the histone H3 substrate, and 81'), Document(id='b04c827c-e220-47fe-8db5-37c54fb6d686', metadata={'link': 'https://doi.org/10.1016/j.patter.2021.100433', 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'id': 74, 'file': '26.pdf', 'type': 'result', 'year': 2022}, page_content='of 4 trials were found). A patent search via dedicated concept queries and analysis of disease-related topics (Medical Subject Headings [MeSH]) extended the coverage of the elucidated contextual information. For Debio-1347 and GW441756X compounds, cancer-related terms dominated the results, with a relevance score (Kullback-Leibler divergence) of 6.12 for ‘‘small cell lung carcinoma’’ (Debio-1347) and 5.98 for ‘‘glioblastoma’’ (GW441756X),'), Document(id='f1a755f3-185a-450a-82e1-8be02ac275dd', metadata={'type': 'result', 'title': 'A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism', 'file': '26.pdf', 'id': 74, 'year': 2022, 'link': 'https://doi.org/10.1016/j.patter.2021.100433'}, page_content='pTau.19 According to Carlomagno ., HDAC6 mediated deacetylation of tau at certain sites (such as K321; Figure 3A), which also allow for phosphorylation of the tau protein (pTau).24 One such study reported that HDAC6 activity at K280 and K281 positively correlated with the pTau protein abundance,25 while another group demonstrated that a direct acetylation of MAPT was shown to favor the generation of pathological pTau aggregates.26 The study'), Document(id='00c90ae5-42d2-47e3-bc8e-570684d0800b', metadata={'year': 2024, 'file': '29.pdf', 'title': 'Genomics and Drug Research Approach in Identifying Potential Drug Target Highlighting Alzheimer Disease', 'type': 'abstract', 'link': 'https://doi.org/10.52403/gijhsr.20240115', 'id': 78}, page_content='chromen-4-one as potent bioactive compound presenting high docking score of -5.60 K cal/mol against BACE1 followed by other compounds. This identification will open new scope to future researchers to explore more bioactive compounds which may aid new treatment options against AD followed with wet lab experimentation.'), Document(id='8481ad85-e61c-41c8-9fc0-5551da82b79d', metadata={'file': '15.pdf', 'type': 'result', 'year': 2024, 'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease"", 'id': 44}, page_content='of DAPK1 in the cell [52, 53]. Sanggenon C upregulates the cellular DAPK1 level by stabilizing the protein, leading to cell cycle arrest and apoptosis in glioblastoma model [220]. Grifolin has been reported to upregulate the cellular p53 function and promote the transcription and expression of DAPK1 in breast cancer cell lines, thus promoting cancer cell death [221]. Curcumin has also been shown to cause cell cycle arrest and apoptosis in cancer')]","Out of 104 compounds inhibiting HDAC6 by at least 75%, how many were found to be specific for the histone H3 substrate in the second screening?",3,3,2,8,1
8,"SIRT1 is a member of the Sirtuin family of NAD+-dependent deacetylases (Identification of Sirtuin 1-Targeted Anti-Alzheimer Agents Using Structure-Based Drug Design and Multi-Database Screening, https://doi.org/10.56042/ijc.v63i12.13637)","[Document(id='2d21fbe0-7494-4af0-9ac1-819f871a7513', metadata={'year': 2024, 'type': 'introduction', 'id': 82, 'link': 'https://doi.org/10.56042/ijc.v63i12.13637', 'file': '31.pdf', 'title': 'Identification of Sirtuin 1-Targeted Anti-Alzheimer Agents Using Structure-Based Drug Design and Multi-Database Screening'}, page_content=""treatments only offer limited symptomatic relief. Consequently, there is a pressing need for novel therapeutic approaches to address the disease's underlying causes and halt its progression4,5. Sirtuin1 (SIRT1) is a member of the Sirtuin family of NAD+-dependent deacetylases and has garnered significant attention due to its involvement in regulating various cellular processes, including ageing, metabolism, and stress responses6. In the context""), Document(id='9bbc2cd9-37fb-491f-b5ca-01b2f4450192', metadata={'file': '31.pdf', 'link': 'https://doi.org/10.56042/ijc.v63i12.13637', 'title': 'Identification of Sirtuin 1-Targeted Anti-Alzheimer Agents Using Structure-Based Drug Design and Multi-Database Screening', 'type': 'result', 'id': 83, 'year': 2024}, page_content='shown in Fig. 4. These values suggest efficient binding of the ligands with the sirt1 enzyme22,23. The lower RMSD values indicate a relatively stable and consistent binding of these ligands within the enzyme’s active site across the simulation time frame. Root Mean Square Fluctuation (RMSF), is an important feature that has to be considered when evaluating the structural flexibility of proteins during MD. In addition to assisting in the'), Document(id='354c971a-f153-4990-bdb7-7869f41600ad', metadata={'type': 'result', 'title': 'Identification of Sirtuin 1-Targeted Anti-Alzheimer Agents Using Structure-Based Drug Design and Multi-Database Screening', 'file': '31.pdf', 'id': 83, 'link': 'https://doi.org/10.56042/ijc.v63i12.13637', 'year': 2024}, page_content='to evaluate the potential of these compounds against sirt1, multiple experimental verifications must be carried out. An efficient way to determine whether or not the molecules have a strong affinity for one another is the Surface Plasmon Resonance (SPR) test. A kinetic study is an appropriate method to investigate the processes that are responsible for the binding and unbinding of these molecules. Based on the results of the experiments, more'), Document(id='dd9edc7c-020d-4071-96da-ca540f38862e', metadata={'file': '0.pdf', 'year': 2022, 'link': 'https://doi.org/10.3389/fnagi.2021.809433', 'title': ""Salidroside Ameliorates Alzheimer's Disease by Targeting NLRP3 Inflammasome-Mediated Pyroptosis"", 'type': 'result', 'id': 2}, page_content='(Figure 9J). Thus, the above results conﬁrmed that Sal inhibited pyroptosis mainly through targeting suppression of the NLRP3 inﬂammasome. NLRP3 Is Involved in the Inhibitory Effect of Sal on D-gal-Induced PC12 Cells Pyroptosis We hypothesized that Sal acts against D-gal-induced NLRP3 inﬂammasome activation by downregulating NLRP3. To test this, we knocked down NLRP3 expression in PC12 cells by siRNA. Firstly, the Western blot result showed that'), Document(id='4d587f6e-a7be-4d0d-a864-a33c7de5cc5c', metadata={'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease"", 'id': 44, 'type': 'result', 'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'file': '15.pdf', 'year': 2024}, page_content='bind to DAPK1, it remains elusive whether these molecules indeed exert protective effects through inhibiting DAPK1 in vitro and in vivo. There are also natural compounds that can upregulate DAPK1 function in cells. For instance, Sanggenon C is able to decrease the expression of the E3 ubiquitin ligase Mind-bomb 1 (Mib1, also known as DIP-1), an important binding partner controlling the degradation of DAPK1 in the cell [52, 53]. Sanggenon C')]","To which family of deacetylases does SIRT1 belong, and upon which cofactor is its activity dependent?",3,3,2,8,1
9,"According to the article “The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease” (https://doi.org/10.3389/fpsyt.2022.1039725), substantial apoptotic cell death of VTA dopamine neurons and significant local neuroinflammation in Tg2576 mice starts between 2–3 months of age and progressively worsens with age.","[Document(id='66b6c3b0-ab44-497d-90a1-b3129c4ab798', metadata={'type': 'result', 'year': 2022, 'id': 29, 'file': '9.pdf', 'link': 'https://doi.org/10.3389/fpsyt.2022.1039725', 'title': ""The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer's disease""}, page_content='evidence linking the dopaminergic VTA with these early deficits in Tg2576 mice came after the observation of substantial apoptotic cell death of VTA dopamine neurons in these mice, accompanied by significant levels of local neuroinflammation, starting between 2–3 months of age and progressively worsening with age (111). The work by Nobili, ., and subsequent papers, showed that the progressive degeneration of VTA TH+ neurons results in lower'), Document(id='54c4bd25-46e1-4149-b40e-e2821680215c', metadata={'year': 2024, 'type': 'result', 'file': '15.pdf', 'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease"", 'id': 44, 'link': 'https://doi.org/10.1186/s40035-023-00395-5'}, page_content='promoting the generation of interleukin-1β (IL-1β) and subsequent cognitive impairments in vitro and in vivo [157]. Neuronal cell death is commonly observed during neural development and pathological conditions [158]. The programmed cell death in the developmental period contributes to the elimination of redundant neurons, which is crucial for the establishment of functional neural circuits and the maintenance of normal organ size [158]. The'), Document(id='4a5f9a51-84f7-4feb-9d83-93e28af121c1', metadata={'type': 'result', 'link': 'https://doi.org/10.1186/s40035-023-00395-5', 'title': ""Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease"", 'id': 44, 'file': '15.pdf', 'year': 2024}, page_content='monitor disease progression. In AD mouse models, whether DAPK1 expression or function is dysregulated remains controversial in literature. Hainsworth . determined DAPK1 expression in brains of aged Tg2576 transgenic mice overexpressing the APP Swedish mutant and found that the DAPK1 protein level was comparable between AD mice and wild-type (WT) controls [97]. However, the expression of DAPK1 was significantly upregulated in the hippocampus of'), Document(id='12b74a7f-0dc2-47f9-aca3-5dde3b5140ce', metadata={'year': 2021, 'title': ""A dual-targeted multifunctional nanoformulation for potential prevention and therapy of Alzheimer's disease"", 'link': 'https://doi.org/10.1016/j.xinn.2021.100160', 'file': '18.pdf', 'type': 'result', 'id': 53}, page_content='damage during the entire process of AD. In the early stage of AD, PTCN also signiﬁcantly inhibited inﬂammation and mildly inhibited neuronal apoptosis. In contrast, in the late stage of AD, PTCN weakly reduced inﬂam-mation but signiﬁcantly enhanced apoptosis inhibition. These results demonstrate that PTCN administration via a gradient dosing strategy can effectively and continuously attenuate oxidative damage throughout different AD stages, thus'), Document(id='0f9498a9-a297-489d-a463-4c92635ff7d4', metadata={'link': 'https://doi.org/10.1002/alz.13095', 'year': 2023, 'id': 47, 'title': ""Sex‐specific declines in cholinergic‐targeting tRNA fragments in the nucleus accumbens in Alzheimer's disease"", 'file': '16.pdf', 'type': 'result'}, page_content='we did not observe similar increases in female originated cell lines: the levels of only 38% (118/308) of CholinotRFs were elevated (compared with 35% of non-cholinergic tRFs, 247/710, Fisher’s exact test p < 0.29; Figure 5B; TableS15). Since a previous study reported that neuronal cholinergic differentiation is a slower process that matures around 4 days,43 we further examined tRF levels 4 days after exposure to neurokines. At this time point,')]",At what age do Tg2576 mice begin to show substantial apoptotic cell death of VTA dopamine neurons and significant local neuroinflammation?,3,3,2,8,1
